177Lu-capromab pendetide (CYT 500) / Jazz - LARVOL DELTA

Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends. (PubMed, Cancers (Basel)) - "[In]In-capromab pendetide scintigraphy was a new approach in the management of PCa. Here, we recapitulate the role of targeted functional imaging. We briefly mention the most popular radiotracers, their diagnostic accuracy in the primary staging of PCa, and impact on patient management."

Clinical • Journal • Review • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • MRI

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives. (PubMed, Cancers (Basel)) - "Recently, investigators started to focus on treating prostate cancer patients in earlier disease stages and in combination with other compounds. This review gives a brief overview of the current state and the future perspectives of Lu labelled PSMA radioligand therapy."

Journal • Review • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

[VIRTUAL] Patient travel challenges in the rra of PPRT (ENETS 2021) - "Most commonly used forms of PRRT are Lutetium 177 labelled DOTATATE (Lutathera, Advanced Accelerator Applications, a Novartis company) which was recently approved by U.S. Food and Drug Administration (FDA) and Yttrium 90 labelled DOTATATE. Traveling while undergoing PRRT should be discussed with the patient by the clinical care team and nuclear medicine/nuclear radiology team prior to treatment to avoid any unwanted surprises. Patients can arrange their schedules accordingly if they are well informed about this process ahead of time."

Clinical • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • SSTR

Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer. (PubMed, Target Oncol) - "Our findings suggest that Lu-PSMA radioligand therapy provides a significant response rate with a low toxicity profile. The evidence promotes greater efficacy of radioligand therapy in predominantly lymph node metastatic castration-resistant prostate cancer, and in individuals with chemotherapy-naïve status and lower levels of baseline PSA."

Clinical • Journal • Real-World Evidence • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate Lu-NNV003. (PubMed, Eur J Nucl Med Mol Imaging) - "Lu-NNV003 had a significant anti-tumour effect and a favourable toxicity profile. These results warrant further clinical testing in patients with CD37-expressing B cell malignancies."

Journal • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. (PubMed, Nucl Med Commun) - "Ga-DOTATATE and I-mIBG scans yield complementary information. For a more comprehensive assessment, consideration could be given to the use of both I-mIBG and Ga-DOTATATE imaging scans. Because of the heterogeneity of distribution of molecular targets revealed by these techniques, a combination of both I-mIBG and Lu-DOTATATE molecular radiotherapy may possibly be more effective than either alone."

Biomarker • Journal • Neuroblastoma • Oncology • Solid Tumor

Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer. (PubMed, Cancer Rep (Hoboken)) - "This report discusses in detail the homing moieties used in the development of targeted diagnostic tools for detection of PCa. The merits and demerits of monoclonal antibodies, small molecule ligands, peptides, and aptamers for imaging of PCa and intraoperative guided surgery are extensively analyzed. Among all, urea-based ligands were found to be most successful in preclinical and clinical trials and show a major promise for future commercialization."

Clinical • Journal • Review • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Prostate-specific membrane antigen theranostics: therapy with lutetium-177. (PubMed, Curr Opin Urol) - "Several studies suggest that radionuclide therapy with Lu-PSMA has high activity and is well tolerated. Crucial to establishing this treatment in routine clinical management will be the generation of high-level evidence from prospective trials that can confirm the encouraging patient outcomes reported to date."

Journal